Biogen Is ‘Evaluating Strategic Options’ For Its Biosimilars Business
CEO Says ‘Formal Process Is Underway’ To Consider Selling To A New Owner
Executive Summary
Biogen revealed that a formal process is now underway to “evaluate strategic options” for its biosimilars business, pointing to a potential transfer of the unit to a new owner.
You may also be interested in...
Dr Reddy’s Is Latest Rumored Buyer For Biogen’s Biosimilars
With Biogen having put its biosimilars interests on the market, multiple bidders appear to be interested in the business. Dr Reddy’s has become the latest firm to be named in media reports as vying for a deal.
Deal Watch: Dianthus Will Reach Public Markets Via Reverse Merger With Stalled-Out Magenta
After shutting down its trial for a leukemia conditioning agent due to a patient death, Magenta’s review of strategic alternatives concludes with a combination with complement inhibitor-focused Dianthus.
Stada, Biogen Bring Greater Ranibizumab Competition To EU And UK
April brings news of further biosimilar competition to Lucentis in major European markets.